Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Non-Current Debt (2024 - 2025)

Karyopharm Therapeutics' Non-Current Debt history spans 2 years, with the latest figure at $94.8 million for Q4 2025.

  • For Q4 2025, Non-Current Debt changed 0.2% year-over-year to $94.8 million; the TTM value through Dec 2025 reached $94.8 million, changed 0.2%, while the annual FY2025 figure was $94.8 million, 0.2% changed from the prior year.
  • Non-Current Debt reached $94.8 million in Q4 2025 per KPTI's latest filing, up from $83.9 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $95.2 million in Q1 2025 to a low of $83.9 million in Q3 2025.